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Over the past decade, quality measures (QMs) have been
implemented nationally in order to establish standards
aimed at improving the quality of care. With the expansion
of their role in the Affordable Care Act and pay-for-perfor-
mance,QMshavehad an increasingly significant impact on
clinical practice. However, adverse patient outcomes have
resulted from adherence to some previously promulgated
performance measures. Several of these QMs with unin-
tended consequences, including the initiation of periopera-
tive beta-blockers in noncardiac surgery and intensive in-
sulin therapy for critically ill patients, were instituted as
QMs years before large randomized trials ultimately refuted
their use. The future of quality care should emphasize the
importance of evidence-based, peer-reviewed measures.
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INTRODUCTION
Over the past decade, quality measures (QMs) have assumed a
crucial role in the healthcare landscape. With the advent of
pay-for-performance and public reporting of hospital and phy-
sician adherence to quality guidelines, the development of
safe, practical QMs is more important than ever. The Afford-
able Care Act (ACA) now mandates that the Centers for
Medicare and Medicaid Services (CMS) increase the scope
of pay-for-performance nationally. As part of this new legis-
lation, value-based purchasing expands the role of pay-for-
performance in quality improvement. Hospitals will now be
offered incentive payments derived from a list of 25 different
QMs.1 Yet despite advances in healthcare quality improve-
ment practices, not all QMs have proven to be of value. This is
particularly the case when new data emerge that countervail
the evidence on which the QMwas originally based. There are
multiple QMs that have fallen short of their intended objec-
tives or that have even led to patient harm (see Table 1). Given
the potential for adverse consequences, the conversion of
guidelines into performance measures should not occur with-
out adequate high-quality evidence. In this discussion, we
examine two QMs that have had widespread effects on patient
care, and that may have led to increased mortality: perioper-
ative beta-blockers and glucose control in critically ill patients.
We also explore the use of patient safety indicators and re-
duced 30-day readmission rates, which have an increasing role
in the assessment of hospital quality and compensation.
PERIOPERATIVE BETA-BLOCKERS
Worldwide, 100 million patients undergo noncardiac surgery
every year. It is estimated that 10-40 % of these procedures are
complicated by a major adverse cardiac event.22 First intro-
duced into the literature in 1973, perioperative beta-blockers
(PBB) were suggested as a preoperative maneuver to reduce
the mortality of patients undergoing noncardiac surgery.23
However, it was not until publication of the Dutch Echocar-
diographic Cardiac Risk Evaluation Applying Stress Echo
(DECREASE) trials that PBB became a commonly employed
metric of quality.
The DECREASE I trial, published in 1999 by a team led by
Dutch researcher Don Poldermans, was halted prior to comple-
tion due to a reported overwhelming survival benefit seen in the
beta-blocker arm.24 After the results of DECREASE I were
reported, the Agency for Healthcare Research and Quality
(AHRQ) identified PBB as one of the Bclear opportunities for
safety improvement;^ the National Quality Forum put PBB on
its list of 30 Safe Practices for Better Healthcare; and the
Physician Consortium and the Surgical Care Improvement
Project designated PBB as a QM.25 Poldermans continued to
publish new data as part of the DECREASE trials, notably
DECREASE IV, which demonstrated an additional survival
benefit with the use of PBB in intermediate-risk patients.26
In 2008, the results of POISE, the largest randomized
controlled trial (RCT) to have been reported at that time, with
over 8,000 participants, found a significant increase in mor-
tality among patients randomized to beta-blockers versus pla-
cebo.2 Despite these new data, both the European Society of
Cardiology (ESC) and the American College of Cardiology
Foundation/American Heart Association (ACCF/AHA) joint
guidelines continued to recommend PBB, with the ESC citing
it as a class I recommendation.27
In September 2012, the Netherlands-based Erasmus Medi-
cal Center released the final report of an investigation of
suspected research misconduct in the DECREASE trials.28
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After thorough examination, the committee concluded that
there were multiple instances of scientific misconduct repre-
sented in the collection, analysis, and representation of source
data.
Subsequent to this announcement, a meta-analysis pub-
lished in 2013 with consolidated outcomes of over 10,000
randomized participants showed that initiation of PBB before
surgery caused a significant increase in mortality, whereas the
DECREASE data had shown a non-significant reduction in
mortality.29 It was only after additional RCTs had countered
the results of DECREASE that, in 2014, the ESC guidelines
recommended against the initiation of PBB for patients under-
going low- to intermediate-risk noncardiac surgery.30
GLUCOSE CONTROL IN CRITICALLY ILL PATIENTS
Stress-induced hyperglycemia is a known complication
among critically ill patients. Multiple studies have shown
hyperglycemia to be linked to increased mortality in both
diabetic and non-diabetic cohorts. An initial trial in the surgi-
cal intensive care unit showed a mortality benefit with inten-
sive insulin therapy (IIT).31 Based on this RCT in surgical
patients, strict glucose control was recommended as a QM in
the Surgical Care Improvement Program.32 Citing grade A
evidence, the American Association of Clinical Endocrinolo-
gists and the American Diabetes Association issued recom-
mendations in 2007 and 2008, respectively, advising tight
glucose control in the critically ill population.33,34 Thus,
although originally recommended for surgical patients in in-
tensive care, the QM also began to be used among patients in
non-surgical intensive care units. In 2009, the NICE-SUGAR
trial, which enrolled both surgical and non-surgical patients,
showed increased rather than decreased mortality rates and
more frequent hypoglycemic episodes with intensive glucose
control at 90 days.3 Ameta-analysis published in 2011 showed
no clear mortality benefit with IIT; once again, IIT was asso-
ciated with increased risk of hypoglycemia.4 That same year,
the American College of Physicians released guidelines stat-
ing that IIT should not be used in critically ill patients, either
with or without diabetes.35
PATIENT SAFETY INDICATORS
Patient safety indicators (PSIs) were released by AHRQ in
March 2003 to identify post-surgical or post-procedural com-
plications of inpatient care using billing information as a
screening mechanism. PSIs are playing a greater role in
QMs, as U.S. News recently announced that patient safety
will be a more heavily weighted score in its Best Hospitals
ranking system.36 Of the 17 total PSIs, eight comprise 10 % of
the overall score in the new algorithm for this popular ranking
system, double the 5 % contribution to the score the previous
year.
The current list of PSIs is extensive, including complica-
tions such as iatrogenic pneumothorax, postoperative sepsis,
and postoperative hemorrhage or hematoma. However, a 2008
study by Isaac and Jha found largely poor or inverse correla-
tions between several PSIs and other hospital quality stand-
ards.17 These PSIs were poorly correlated with other process
metrics and in-hospital mortality. Multiple other studies have
investigated various PSIs. One looked at the validity of 12
different PSIs and found moderate positive predictive values
for most of the quality indicators in detecting true safety
events, concluding that these indicators required revision be-
fore their use as pay-for-performance measures.18 Similar
conclusions were formed in several other studies validating
PSIs for postoperative pulmonary embolus and VTE, iatro-
genic pneumothorax, accidental puncture and laceration, cen-
tral venous catheter-related bloodstream infections, and post-
operative respiratory failure.19–21 Despite the lack of mean-
ingful correlation between these PSIs and other process-of-
care metrics, at this writing, they continue to have a role in
hospital compensation and public reporting.
THIRTY-DAY READMISSIONS
On October 1, 2012, CMS began penalizing hospitals for
higher readmission rates for heart failure, acute myocardial
infarction, and pneumonia as part of the Hospital Readmis-
sions Reduction Program (HRRP). Of note, about 25 % of all
patients discharged after admission for heart failure are read-
mitted within this 30-day bracket.37 However, it is unclear
Table 1 Complications Reported from Studies Evaluating Quality




Perioperative beta-blockers2 Increased mortality, risk of stroke
and hypotension; decreased risk
of nonfatal myocardial infarction







No association between early
antibiotics and outcomes
Blood pressure control in chronic
kidney disease6
Increased mortality rates with
lower diastolic pressures
Patient satisfaction in surgical
care7–9
No association with hospital
compliance with surgical quality
measures
Prophylactic antibiotics for major
surgical procedures10







Length of hospital stay12 Not positively correlated with
quality of care
30-day readmissions13,14 Multiple factors that lead to
readmission, <20 % deemed
preventable
Venous thromboembolism15 Limited utility from surveillance
bias
Hospital-acquired pressure ulcers16 Difference in administrative vs
surveillance incidence
Patient safety indicators17–21 Unable to assess preventable
events, low positive predictive
value
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whether the factors that influence hospital readmission rates
are inherently beyond their control. A study by Joynt and Jha
found that many of these factors were related to characteristics
of the patient population and their community resources, such
as poverty, mental illness, social support, and good access to
care,38 yet no specific targets for improvement were found that
would be successful in preventing future readmissions. In an
Ontario study, investigators found that less than one-fifth of
readmissions within 6 months were actually preventable.39
Based on the pattern of reimbursement cuts, one study has
shown that large teaching hospitals and safety-net hospitals are
most likely to be penalized, suggesting that higher readmission
rates might be due to lower socioeconomic status and greater
case complexity.38
Currently the scope of HRRP is increasing. For the next
fiscal year, CMS has expanded its list of diagnoses that will
incur a readmission penalty to include acute myocardial in-
farction, heart failure, pneumonia, chronic obstructive pulmo-
nary disease, and total hip or knee arthroplasty; in addition, the
maximum Medicare reimbursement reduction will increase
from 2 % to 3 %.39
DISCUSSION
The translation of guidelines into performance measures
requires a discriminating approach. Guidelines are a series of
expert recommendations based on scientific evidence, and
QMs are the next step in the evolutionary process of influenc-
ing care. Much more than a recommendation, a performance
measure is a mandate that affects fiscal compensation and
public reputational standing. QMs influence patient care, in-
stitutional compliance, and organizational financial well-be-
ing. In order to bolster the validity of performance measures
and reinforce their impact, attention needs to be focused not
only on developing guidelines, but also on the conversion of
these guidelines to QMs. This evolution must be based on the
best and most clinically relevant evidence available.
Clinical practice guidelines represent the consensus of
experts, ideally based on evidence. However, the transfor-
mation of guidelines into QMs and pay-for-performance
measures may antedate and even preempt the collection of
high-quality evidence. In an analysis of class I ACC/AHA
guideline recommendations over a period of several years,
revisions in recommendations were found most commonly
among those not verified by multiple RCTs.40 Clinicians
may prematurely endorse and propagate new guidelines
based on Bconsensus validity,^ when the consensus process
itself—sometimes at the expense of other, more relevant
criteria—determines the content and/or adoption of new
guidelines.41 Guidelines can also be influenced by panel
members and their societies’ interests, and are not always
just the result of evidence or good clinical judgment. The
recent scandal involving a member of the National Quality
Forum, who was allegedly paid over $11 million to endorse
measures that would be financially favorable to his sponsor,
serves to reinforce this serious concern.42
Future QMs need to be evaluated in a more rigorous and
evidence-based manner. With the initiation of value-based
purchasing as part of the new ACA standards, a greater num-
ber of QMs will now be proposed and marketed on a national
platform and will require constant vigilant examination. To
reduce the burden of unsafe practice, QMs must be subject to
stringent scientific scrutiny, and hence must allow for peer-
reviewed pay-for-performance (PR-P4P). A process such as
PR-P4P is a directive with the goal of optimal fusion of
economic incentives and patient-centered care. Although the
past decade will undoubtedly be remembered for the gains
made in patient safety and quality of care, continued improve-
ment will require greater attention to the principles of scientific
rigor in assessing measures of patient care quality and safety.
Conflict of Interest: The authors each declare that they have no
conflicts of interest.
Corresponding Author: Deeb N. Salem, MD; Department of
Med i c ine , Tu f ts Med ica l Cen te r, Bos ton , MA, USA
(e-mail: DSalem@tuftsmedicalcenter.org).
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
REFERENCES
1. Centers for Medicare and Medicaid Services. Fact sheets: CMS final rule to
improve quality of care during hospital inpatient stays. Available at: http://
www.cms.gov/newsroom/mediareleasedatabase/fact-sheets/2013-fact-
sheets-items/2013-08-02-3.html. Accessed February 20, 2015.
2. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release
metoprolol succinate in patients undergoing non-cardiac surgery (POISE
trial): a randomised controlled trial. Lancet. 2008;371:1839–1847.
3. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose
control in critically ill patients. N Engl J Med. 2009;360(13):1283–1297.
4. Kansagara D, Fu R, Freeman M, Wolf F, Helfand M. Systematic review:
intensive insulin therapy in hospitalized patients. Ann Intern Med.
2011;154:268–282.
5. Yu KT, Wyer PC. Evidence-based emergency medicine/critically appraised
topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in
community-acquired pneumonia. Ann Emerg Med. 2008;51(5):651–662.
662.e1-2.
6. Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood pressure and mortality
in US veterans with chronic kidney disease. Ann Intern Med.
2013;159:233–242.
7. Lyu H, Wick EC, Housman M, Freischlag JA, Makary MA. Patient
satisfaction as a possible indicator of quality surgical care. JAMA Surg.
2013;148(4):362–367.
8. Chang JT, Hays RD, Shekelle PG, et al. Patients’ global ratings of their
health care are not associated with the technical quality of their care. Ann
Intern Med. 2006;144(9):665–672.
9. Fenton JJ, Jerant AF, Bertakis KD, Franks P. The cost of satisfaction: a
national study of patient satisfaction, health care utilization, expenditures,
and mortality. Arch Intern Med. 2012;172(5):405–411.
10. Hawn MT, Itani KM, Gray SH, Vick CC, Henderson W, Houston TK.
Association of timely administration of prophylactic antibiotics for major
surgical procedures and surgical site infection. J Am Coll Surg.
2008;206:814–819.
11. Fonarow GC, Abraham WT, Albert NM, et al. Association between
performance measures and clinical outcomes for patients hospitalized with
heart failure. JAMA. 2007;297(1):61.
1206 Esposito et al: Quality Measures in Pay-for-Performance JGIM
12. Consumer Reports. Available at: http://www.consumerreports.org/
health/doctors-hospitals/hospital-ratings.htm. Accessed February 20,
2015.
13. Joynt KE, Jha AK. Thirty-day readmissions: truth and consequences. N
Engl J Med. 2012;366(15):1366–1369.
14. Van Walraven C, Jennings A, Taljaard M, et al. Incidence of potentially
avoidable urgent readmissions and their relation to all-cause urgent
readmissions. CMAJ. 2011;183:E1067–E1072.
15. Bilimoria KY, Chung J, Ju MH, et al. Evaluation of surveillance bias and
the validity of the venous thromboembolism Quality Measure. JAMA.
2013;310(14):1482–1489.
16. Meddings JA, Reichert H, Hofer T, McMahon LF Jr. Hospital report
cards for hospital-acquired pressure ulcers: how good are the grades? Ann
Intern Med. 2013;159(8):505–513.
17. Isaac T, Jha AK. Are patient safety indicators related to widely used
measures of hospital quality? J Gen Intern Med. 2008;23:1373–1378.
18. Rosen AK, Itani KM, Cevasco M, et al. Validating the patient safety
indicators in the Veterans Health Administration: do they accurately
identify true safety events? Med Care. 2012;50(1):74–85.
19. Kaafarani HM, Borzecki AM, Itani KM, et al. Validity of selected patient
safety indicators: opportunities and concerns. J Am Coll Surg.
2011;212(6):924–934.
20. Cevasco M, Borzecki AM, O’Brien WJ, et al. Validity of the AHRQ Patient
Safety Indicator BCentral Venous Cather-Related Bloodstream Infections.^.
J Am Coll Surg. 2011;212:984–990.
21. Borzecki AM, Kaafarani HM, Utter GH, et al. How valid is the AHRQ
Patient Safety Indicator BPostoperative Respiratory Failure^? J Am Coll
Surg. 2011;212:935–945.
22. Flynn BC, Wernick WJ, Ellis JE. Beta-blockade in the perioperative
management of the patient with cardiac disease undergoing non-cardiac
surgery. Br J Anaesth. 2011;107(S1):i3–i15.
23. Prys-Roberts C, Foex P, Biro GP, Roberts JG. Studies of anesthesia in
relation to hypertension v. adrenergic beta receptor blockade. Br J Anaesth.
1973;45:67–81.
24. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on
perioperative mortality and myocardial infarction in high-risk patients
undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk
Evaluation Applying Stress Echocardiography Study Group. N Engl J
Med. 1999;341:1789–1794.
25. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin
EM. Perioperative Beta-Blocker Therapy and Mortality after Major Noncar-
diac Surgery. N Engl J Med. 2005;353:349–361.
26. Poldermans D, Schouten O, Bax J, Winkel TA. Reducing cardiac risk in
non-cardiac surgery: evidence from the DECREASE studies. Eur Heart J
Suppl. 2009;11:A9–A14.
27. Sear JW, Foex P. Recommendations on perioperative beta- blockers:
differing guidelines: so what should the clinician do? Br J Anaesth.
2010;104:273–275.
28. Erasmus Medical Center Follow-up Investigation Committee. Report on the




29. Bouri S, Shun-Shin MJ, Cole GD, Mayet J, Francis DP. Meta-analysis of
secure randomised controlled trials of beta-blockade to prevent perioper-
ative death in non-cardiac surgery. Heart. 2013;1–9.
30. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on
non-cardiac surgery: cardiovascular assessment and management. Eur
Heart J. 2014;35:2383–2431.
31. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy
in critically ill patients. N Engl J Med. 2001;345:1359–1367.
32. The Joint Commission. Surgical care improvement project core measure
set. Available at: http://www.jointcommission.org/assets/1/6/Surgi-
cal%20Care%20Improvement%20Project.pdf. Accessed February 20,
2015.
33. American Diabetes Association. Standards of medical care in diabetes-
2008. Diabetes Care. 2008;31(Suppl 1):S12–S54.
34. Rodbard HW, Blonde L, et al. American association of clinical endocrinol-
ogists medical guidelines for clinical practice for the management of
diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1–68.
35. Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P. Use of Intensive
Insulin Therapy for the Management of Glycemic Control in Hospitalized
Patients: A Clinical Practice Guideline From the American College of
Physicians. Ann Intern Med. 2011;154(4):260–267.
36. Harder B. US News hospital rankings to double role of patient safety, cut
back reputation. Available at: http://health.usnews.com/health-news/
blogs/second-opinion/2014/01/11/us-news-hospital-rankings-to-boost-
role-of-patient-safety-cut-back-reputation. Accessed February 20, 2015.
37. Vaduganathan M, et al. Thirty-day readmissions: the clock is ticking.
JAMA. 2013;309(4):345–346.
38. Joynt KE, Jha AK. Characteristics of hospitals receiving penalties under
the Hospital Readmissions Reduction Program. JAMA. 2013;309(4):342–
343.
39. Centers for Medicare and Medicaid Services. Readmissions Reduction
Program. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-
Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.
html. Accessed February 20, 2015.
40. Neuman MD, Goldstein JN, Cirullo MA, et al. Durability of class I
American College of Cardiology/American Heart Association clinical prac-
tice guideline recommendations. JAMA. 2014;311(20):2092–2100.
41. Selker HP. Criteria for adoption in practice of medical practice guidelines.
Am J Cardiol. 1993;71:339–341.
42. National Quality Forum. NQF Statement on Department of Justice
Settlement. Available at: http://www.qualityforum.org/News_And_Resour-
ces/Press_Releases/2014/NQF_Statement_on_Department_of_Justice_
Settlement.aspx. Accessed February 20, 2015.
1207Esposito et al: Quality Measures in Pay-for-PerformanceJGIM
